Валеология: Здоровье, Болезнь, Выздоровление. 2020; : 79-84
КИСТОЗНЫЙ ФИБРОЗ. РЕКОМЕНДАЦИИ ДЛЯ ПЕДИАТРА
Аннотация
В последнее время достигнут определенный прогресс в научном подходе к кистозному фиброзу в результате достижений в области клеточной патологии, генетики и молекулярной биологии. Эта статья представляет собой обзор текущего состояния проблемы кистозного фиброза и затрагивает основные причины, тип наследования, современную терапию и новые достижения в изучении этой патологии. Для педиатра важно понимать, что ранняя диагностика и адекватная терапия не только улучшают течение кистозного фиброза, но и повышают качество жизни больных, позволяя длительно избегать развития необратимых изменений.
Список литературы
1. Муковисцидоз [Электронный ресурс] / под ред. Н. И. Капранова, Н. Ю. Каширской. -Москва: МЕДПРАКТИКА-М, 2014. -672 с. + 1 on-line. (Шифр: 616-056.7 М.90).
2. Розинова Н. Н. Орфанные заболевания легких у детей / Н. Н. Розинова, Ю. Л. Мизерницкий. - Москва: МЕДПРАКТИКА-М, 2015. - 240 с. online. (Шифр 616.24-053.2 Р 64).
3. Орлов А. В. Муковисцидоз: учебное пособие для врачей / А. В. Орлов [и др.]. – СЗГМУ им. И. И. Мечникова. – С. 43-102.
4. Капранов Н. И. Муковисцидоз. Достижения и проблемы на современном этапе / Н. И. Капранов [и др.] // Медицинская.
5. Амелина Е. Л. Муковисцидоз: определение продолжительности жизни / Е. Л. Амелина, А. В. Черняк, А. Л. Черняев // Пульмонология. — 2001. — № 3. — С. 61–64.
6. Капранов Н. И. Муковисцидоз (Современные достижения и проблемы). Методические рекомендации / Н. И. Капранов [и др.] - М.: Медпрактика. – М, 2001. - 76 с.
7. Капранов Н. И. Современные проблемы муковисцидоза / Н. И. Капранов // Гастроэтерология Санкт.Петербурга. — 2002. — № 4. — С. 11–15.
8. Akabas M. H. Cystic Fibrosis Transmembrane Conductance Regulator of CFTR in regulating the pH within intracellular organelles // The journal of biological chemistry — 2000. — V. 275, № 6. — P. 3729–3732.
9. Sinaasappel M., Stern M., Littlewood J. et al. Nutrition in patients with cystic fibrosis: a European Consecsus // Journal of cystic Fibrosis. — 2002. — V. 1. — P. 51–75.
10. Steven V. Molinski, Vijay M. Shahani, Adithya S. Subramanian, Stephen S. MacKinnon, Geoffrey Woollard, et. al.. (2018). Comprehensive mapping of cystic fibrosis mutations to CFTR protein identifies mutation clusters and molecular docking predicts corrector binding site. Proteins. 86, 833-843.
11. David C. Gadsby, Paola Vergani, László Csanády. (2006). The ABC protein turned chloride channel whose failure causes cystic fibrosis. Nature. 440, 477-483.
12. Mark T. Clunes, Richard C. Boucher.(2007). Cystic fibrosis: the mechanisms of pathogenesis of an inherited lung disorder. Drug Discovery Today: Disease Mechanisms.4, 63-72.
13. Cystic fibrosis: a disease of vulnerability to airway surface dehydration. Trends in Molecular Medicine. 13, 231-240.
14. Isabelle Fajac, Claire E. Wainwright. (2017). New treatments targeting the basic defects in cystic fibrosis. La Presse Médicale. 46, e165-e175.
15. Michael J. Welsh, Alan E. Smith. (1993). Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell. 73, 1251-1254.
16. Luigi Maiuri, Valeria Raia, Guido Kroemer. (2017). Strategies for the etiological therapy of cystic fibrosis. Cell Death Differ. 24, 1825-1844.
17. Nadia Ameen, Mark Silvis, Neil A. Bradbury. (2007). Endocytic trafficking of CFTR in health and disease. Journal of Cystic Fibrosis.6, 1-14.
18. Xin Meng, Jack Clews, Vasileios Kargas, Xiaomeng Wang, Robert C. Ford. (2017). The cystic fibrosis transmembrane conductance regulator (CFTR) and its stability. Cell. Mol. Life Sci.. 74, 23-38.
19. Susanna A. McColley. (2016). A safety evaluation of ivacaftor for the treatment of cystic fibrosis. Expert Opinion on Drug Safety. 1-7.
20. N. Pedemonte. (2005). Small-molecule correctors of defective F508-CFTR cellular processing identified by high-throughput screening. Journal of Clinical Investigation. 115, 2564-2571.
21. Jentsch T. J., Stein V., Weinreich F., Zdebik A. A. Molecular Structure and Physiological Function of Chloride Channels // Physiol Rev — 2002. — V. 82. — P. 503–568.
22. Jentsch T. J., Maritzen T., Zdebik A. A. Chloride channel diseases resulting from impaired transepithelial transport or vesicular function // J. Clin. Invest. - 2005. -V. 115. -P. 2039–2046.
23. Akabas M. H. Cystic Fibrosis Transmembrane Conductance Regulator of CFTR in regulating the pH within intracellular organelles // The journal of biological chemistry — 2000. — V. 275, № 6. — P. 3729–3732.
24. Nixon G. M., Armstrong D. S., Carzino R. et al. Early airway infection, inflammation, and lung function in cystic fibrosis // Arch. Dis. Child. — 2002. — V. 87. — P. 306–311.
25. Penny Whiting, Maiwenn A. l., Laura Burgers, Marie Westwood, Steve Ryder, et. al. (2014). Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis. Health Technology Assessment. 18.
26. J. P. Clancy. (2014). CFTR Potentiators: Not an Open and Shut Case. Science Translational Medicine. 6, 246fs27-246fs27.
27. Patrick A. Flume, Theodore G. Liou, Drucy S. Borowitz, Haihong Li, Karl Yen, et. al. (2012). Ivacaftor in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation. Chest. 142, 718-724.
28. F. Van Goor, S. Hadida, P. D. J. Grootenhuis, B. Burton, J. H. Stack, et. al.. (2011). Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proceedings of the National Academy of Sciences. 108, 18843-18848.
29. Xin Meng, Jack Clews, Eleanor R. Martin, Anca D. Ciuta, Robert C. Ford. (2018). The structural basis of cystic fibrosis. Biochm. Soc. Trans. 46, 1093-1098.
30. Tzyh-Chang Hwang, Jiunn-Tyng Yeh, Jingyao Zhang, Ying-Chun Yu, Han-I Yeh, Samantha Destefano. (2018). Structural mechanisms of CFTR function and dysfunction. J. Gen. Physiol.jgp. 201711946.
31. Diane E. Grove, Meredith F. N. Rosser, Richard L. Watkins, Douglas M. Cyr. (2011). Analysis of CFTR Folding and Degradation in Transiently Transfected Cells. Methods in Molecular Biology. 219-232.
32. Xin Meng, Jack Clews, Eleanor R. Martin, Anca D. Ciuta, Robert C. Ford. (2018). The structural basis of cystic fibrosis. Biochm. Soc. Trans. 46, 1093-1098.
33. F. Van Goor, S. Hadida, P. D. J. Grootenhuis, B. Burton, D. Cao, et. al.. (2009). Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proceedings of the National Academy of Sciences. 106, 18825-18830.
34. Sanjay Patel, Ian P. Sinha, Kerry Dwan, Carlos Echevarria, Michael Schechter, Kevin W. Southern. (2015). Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis. Cochrane Database of Systematic Reviews.
35. D. M. Cholon, N. L. Quinney, M. L. Fulcher, C. R. Esther, J. Das, et. al.. (2014). Potentiator ivacaftor abrogates pharmacological correction of F508 CFTR in cystic fibrosis. Science Translational Medicine. 6, 246ra96-246ra96.
36. (2016). Poster Session Abstracts. Pediatr Pulmonol.. 51, S194-S485.
37. Симонова О. И. Эффективность кинезитерапии при муковисцидозе у детей: Автореф. дис. докт. мед. наук / О. И. Симонова. — М., 2001. — 48 с.
38. Амелина Е. Л. Мукоактивная терапия / Е.Л. Амелина, А. В. Черняк, А. Л. Черняев / Под ред. Чучалина А. Г., Белевского А. С. – М.: Издательский дом «Атмосфера», 2006. — 128 с.
39. Doering G., Hoiby N. Ранняя терапия и профилактика поражения лёгких при муковисцидозе. Европейский консенсус // J. Of CF. — 2004. — V. 3(2). — P. 67–91.
40. Орлов А. В. Муковисцидоз (пособие для врачей) / А. В. Орлов. — СПб, 2004. — 63 с.
41. Капранов Н. И. Современные проблемы муковисцидоза / Н. И. Капранов // Гастроэтерология Санкт.Петербурга. — 2002. — № 4. — С. 11–15.
42. Капранов Н. И. Фармакотерапия при бронхолёгочных поражениях у детей, больных муковисцидозом / Н. И. Капранов / Руководство по фармакотерапии в педиатрии и детской хирургии. — М.: Медпрактика, 2002. — Т. 1. — С. 187–201.
43. Капранов Н. И. Муковисцидоз. Современные достижения и актуальные проблемы. Методические рекомендации / Н. И. Капранов [и др.] – Москва: ГУ Медико-генетический научный центр РАМН, 2005.
44. Шерман В. Д. [и др.] // Педиатрия. – № 2. – 2017. – Т. 96. – С. 90 – 98: Муковисцидоз: определение, диагностические критерии, терапия.
45. Клименко В.А. [и др.] // Здоровье ребенка. – Том 12, № 5. – 2017. – С. 631-635: Клиническое наблюдение ребенка, больного муковисцидозом.
46. Муковисцидоз (клиническая картина, диагностика, лечение, реабилитация, диспансеризация): учебное пособие для врачей / А. В. Орлов [и др.]. - 2-е изд., перераб. и доп. - Санкт-Петербург : СЗГМУ им. И. И. Мечникова, 2014. - 160 с. (Шифр 616-056.7(075) М 90).
Valeology: Health - Illnes - recovery. 2020; : 79-84
CYSTIC FIBROSIS. RECOMMENDATIONS OF A PEDIATRICIAN
Abstract
Recently, some progress has been made in the scientific approach h to cystic fibrosis as a result of advances in cell pathology, genetics and molecular biology. This article provides an overview of the current state of the problem of cystic fibrosis and addresses the main causes, type of inheritance, modern therapy and new advances in the study of this pathology. It is important for the pediatrician to understand that early diagnosis and adequate therapy not only improves the course of cystic fibrosis, but also improves the quality of life of patients, allowing long-term avoid development of irreversible changes.
References
1. Mukovistsidoz [Elektronnyi resurs] / pod red. N. I. Kapranova, N. Yu. Kashirskoi. -Moskva: MEDPRAKTIKA-M, 2014. -672 s. + 1 on-line. (Shifr: 616-056.7 M.90).
2. Rozinova N. N. Orfannye zabolevaniya legkikh u detei / N. N. Rozinova, Yu. L. Mizernitskii. - Moskva: MEDPRAKTIKA-M, 2015. - 240 s. online. (Shifr 616.24-053.2 R 64).
3. Orlov A. V. Mukovistsidoz: uchebnoe posobie dlya vrachei / A. V. Orlov [i dr.]. – SZGMU im. I. I. Mechnikova. – S. 43-102.
4. Kapranov N. I. Mukovistsidoz. Dostizheniya i problemy na sovremennom etape / N. I. Kapranov [i dr.] // Meditsinskaya.
5. Amelina E. L. Mukovistsidoz: opredelenie prodolzhitel'nosti zhizni / E. L. Amelina, A. V. Chernyak, A. L. Chernyaev // Pul'monologiya. — 2001. — № 3. — S. 61–64.
6. Kapranov N. I. Mukovistsidoz (Sovremennye dostizheniya i problemy). Metodicheskie rekomendatsii / N. I. Kapranov [i dr.] - M.: Medpraktika. – M, 2001. - 76 s.
7. Kapranov N. I. Sovremennye problemy mukovistsidoza / N. I. Kapranov // Gastroeterologiya Sankt.Peterburga. — 2002. — № 4. — S. 11–15.
8. Akabas M. H. Cystic Fibrosis Transmembrane Conductance Regulator of CFTR in regulating the pH within intracellular organelles // The journal of biological chemistry — 2000. — V. 275, № 6. — P. 3729–3732.
9. Sinaasappel M., Stern M., Littlewood J. et al. Nutrition in patients with cystic fibrosis: a European Consecsus // Journal of cystic Fibrosis. — 2002. — V. 1. — P. 51–75.
10. Steven V. Molinski, Vijay M. Shahani, Adithya S. Subramanian, Stephen S. MacKinnon, Geoffrey Woollard, et. al.. (2018). Comprehensive mapping of cystic fibrosis mutations to CFTR protein identifies mutation clusters and molecular docking predicts corrector binding site. Proteins. 86, 833-843.
11. David C. Gadsby, Paola Vergani, László Csanády. (2006). The ABC protein turned chloride channel whose failure causes cystic fibrosis. Nature. 440, 477-483.
12. Mark T. Clunes, Richard C. Boucher.(2007). Cystic fibrosis: the mechanisms of pathogenesis of an inherited lung disorder. Drug Discovery Today: Disease Mechanisms.4, 63-72.
13. Cystic fibrosis: a disease of vulnerability to airway surface dehydration. Trends in Molecular Medicine. 13, 231-240.
14. Isabelle Fajac, Claire E. Wainwright. (2017). New treatments targeting the basic defects in cystic fibrosis. La Presse Médicale. 46, e165-e175.
15. Michael J. Welsh, Alan E. Smith. (1993). Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell. 73, 1251-1254.
16. Luigi Maiuri, Valeria Raia, Guido Kroemer. (2017). Strategies for the etiological therapy of cystic fibrosis. Cell Death Differ. 24, 1825-1844.
17. Nadia Ameen, Mark Silvis, Neil A. Bradbury. (2007). Endocytic trafficking of CFTR in health and disease. Journal of Cystic Fibrosis.6, 1-14.
18. Xin Meng, Jack Clews, Vasileios Kargas, Xiaomeng Wang, Robert C. Ford. (2017). The cystic fibrosis transmembrane conductance regulator (CFTR) and its stability. Cell. Mol. Life Sci.. 74, 23-38.
19. Susanna A. McColley. (2016). A safety evaluation of ivacaftor for the treatment of cystic fibrosis. Expert Opinion on Drug Safety. 1-7.
20. N. Pedemonte. (2005). Small-molecule correctors of defective F508-CFTR cellular processing identified by high-throughput screening. Journal of Clinical Investigation. 115, 2564-2571.
21. Jentsch T. J., Stein V., Weinreich F., Zdebik A. A. Molecular Structure and Physiological Function of Chloride Channels // Physiol Rev — 2002. — V. 82. — P. 503–568.
22. Jentsch T. J., Maritzen T., Zdebik A. A. Chloride channel diseases resulting from impaired transepithelial transport or vesicular function // J. Clin. Invest. - 2005. -V. 115. -P. 2039–2046.
23. Akabas M. H. Cystic Fibrosis Transmembrane Conductance Regulator of CFTR in regulating the pH within intracellular organelles // The journal of biological chemistry — 2000. — V. 275, № 6. — P. 3729–3732.
24. Nixon G. M., Armstrong D. S., Carzino R. et al. Early airway infection, inflammation, and lung function in cystic fibrosis // Arch. Dis. Child. — 2002. — V. 87. — P. 306–311.
25. Penny Whiting, Maiwenn A. l., Laura Burgers, Marie Westwood, Steve Ryder, et. al. (2014). Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis. Health Technology Assessment. 18.
26. J. P. Clancy. (2014). CFTR Potentiators: Not an Open and Shut Case. Science Translational Medicine. 6, 246fs27-246fs27.
27. Patrick A. Flume, Theodore G. Liou, Drucy S. Borowitz, Haihong Li, Karl Yen, et. al. (2012). Ivacaftor in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation. Chest. 142, 718-724.
28. F. Van Goor, S. Hadida, P. D. J. Grootenhuis, B. Burton, J. H. Stack, et. al.. (2011). Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proceedings of the National Academy of Sciences. 108, 18843-18848.
29. Xin Meng, Jack Clews, Eleanor R. Martin, Anca D. Ciuta, Robert C. Ford. (2018). The structural basis of cystic fibrosis. Biochm. Soc. Trans. 46, 1093-1098.
30. Tzyh-Chang Hwang, Jiunn-Tyng Yeh, Jingyao Zhang, Ying-Chun Yu, Han-I Yeh, Samantha Destefano. (2018). Structural mechanisms of CFTR function and dysfunction. J. Gen. Physiol.jgp. 201711946.
31. Diane E. Grove, Meredith F. N. Rosser, Richard L. Watkins, Douglas M. Cyr. (2011). Analysis of CFTR Folding and Degradation in Transiently Transfected Cells. Methods in Molecular Biology. 219-232.
32. Xin Meng, Jack Clews, Eleanor R. Martin, Anca D. Ciuta, Robert C. Ford. (2018). The structural basis of cystic fibrosis. Biochm. Soc. Trans. 46, 1093-1098.
33. F. Van Goor, S. Hadida, P. D. J. Grootenhuis, B. Burton, D. Cao, et. al.. (2009). Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proceedings of the National Academy of Sciences. 106, 18825-18830.
34. Sanjay Patel, Ian P. Sinha, Kerry Dwan, Carlos Echevarria, Michael Schechter, Kevin W. Southern. (2015). Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis. Cochrane Database of Systematic Reviews.
35. D. M. Cholon, N. L. Quinney, M. L. Fulcher, C. R. Esther, J. Das, et. al.. (2014). Potentiator ivacaftor abrogates pharmacological correction of F508 CFTR in cystic fibrosis. Science Translational Medicine. 6, 246ra96-246ra96.
36. (2016). Poster Session Abstracts. Pediatr Pulmonol.. 51, S194-S485.
37. Simonova O. I. Effektivnost' kineziterapii pri mukovistsidoze u detei: Avtoref. dis. dokt. med. nauk / O. I. Simonova. — M., 2001. — 48 s.
38. Amelina E. L. Mukoaktivnaya terapiya / E.L. Amelina, A. V. Chernyak, A. L. Chernyaev / Pod red. Chuchalina A. G., Belevskogo A. S. – M.: Izdatel'skii dom «Atmosfera», 2006. — 128 s.
39. Doering G., Hoiby N. Rannyaya terapiya i profilaktika porazheniya legkikh pri mukovistsidoze. Evropeiskii konsensus // J. Of CF. — 2004. — V. 3(2). — P. 67–91.
40. Orlov A. V. Mukovistsidoz (posobie dlya vrachei) / A. V. Orlov. — SPb, 2004. — 63 s.
41. Kapranov N. I. Sovremennye problemy mukovistsidoza / N. I. Kapranov // Gastroeterologiya Sankt.Peterburga. — 2002. — № 4. — S. 11–15.
42. Kapranov N. I. Farmakoterapiya pri bronkholegochnykh porazheniyakh u detei, bol'nykh mukovistsidozom / N. I. Kapranov / Rukovodstvo po farmakoterapii v pediatrii i detskoi khirurgii. — M.: Medpraktika, 2002. — T. 1. — S. 187–201.
43. Kapranov N. I. Mukovistsidoz. Sovremennye dostizheniya i aktual'nye problemy. Metodicheskie rekomendatsii / N. I. Kapranov [i dr.] – Moskva: GU Mediko-geneticheskii nauchnyi tsentr RAMN, 2005.
44. Sherman V. D. [i dr.] // Pediatriya. – № 2. – 2017. – T. 96. – S. 90 – 98: Mukovistsidoz: opredelenie, diagnosticheskie kriterii, terapiya.
45. Klimenko V.A. [i dr.] // Zdorov'e rebenka. – Tom 12, № 5. – 2017. – S. 631-635: Klinicheskoe nablyudenie rebenka, bol'nogo mukovistsidozom.
46. Mukovistsidoz (klinicheskaya kartina, diagnostika, lechenie, reabilitatsiya, dispanserizatsiya): uchebnoe posobie dlya vrachei / A. V. Orlov [i dr.]. - 2-e izd., pererab. i dop. - Sankt-Peterburg : SZGMU im. I. I. Mechnikova, 2014. - 160 s. (Shifr 616-056.7(075) M 90).
